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Abstract
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Prescription drug abuse represents a national public
health concern. This study reports on 12-month outcomes
of a drug court treatment program for 102 female offenders addicted to prescription drugs. The program utilized two
evidence-based treatment models (i.e., Motivational Enhancement Therapy/Cognitive Behavioral Therapy-12 and
Seeking Safety). In addition, participants were required to
attend monthly judicial reviews, weekly AA/NA groups, and
two random drug screens per week. Participants were interviewed at baseline and 12-month follow-up. Analyses examined self-reported substance use, traumatic experiences,
criminal justice involvement, readiness to change, and therapeutic alliance. Participants reported significant decreases in substance use, increased readiness to change, high
therapeutic alliance, and significantly fewer arrest charges
12-months after enrollment compared to 12-months before intake. Results suggest that the drug court program
was successful in reducing substance use and other ancillary measures for female participants with prescription drug
abuse issues. Implications for policy and future research are
discussed.
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Introduction
Of particular concern is the increase of prescription pain killer abuse among arrestees. Using data from the Arrestee Drug
Abuse Monitoring Program (ADAM), the National Survey on
Drug Use and Health (NSDUH) reported that of those arrested
for serious offenses within the past year, illicit drug use was reported almost five times more frequently when compared to
those not arrested within the past year [3]. When considering
drug of choice, the nonmedical use of prescription drugs was

In Florida, more than 60% of people arrested are either under the influence of drugs or alcohol or committing a crime to
obtain narcotics [1]. However, many crimes committed by substance abusers are nonviolent [2]. Unfortunately, the criminal
system is ill-equipped to address the underlying issues of substance abuse. All too often, untreated offenders are released
from jail or prison only to commit more crimes related to drugs
and alcohol, resulting in increased incarceration rates.
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second only to marijuana. According to NSDUH, 28.8% of those
within the sample who had committed serious criminal offenses
within the past year reported nonmedical use of a prescription
drug, compared to only 5.7% of those within the sample that
had not been arrested within the past year.

tal studies conducted; 2) previous meta-analytic reviews have
found that, among the most methodologically rigorous studies,
weaker evidence supporting drug courts’ effectiveness in reducing criminal recidivism has been obtained; and 3) the long-term
duration of drug courts’ effects on criminal recidivism is also
unclear, with many studies only following participants for 12
months, which may or may not overlap with program participation.

Over the past decade, the availability of prescription drugs
has increased dramatically [4]. While clinicians have an array
of analgesics to treat pain, not all medical professionals are responsible when dispensing these powerful medications. From
2000 to 2006, there was an 80% increase in prescription drug
abuse; it now ranks behind only marijuana as the most abused
drug in the U.S [5]. Recent surveys indicate almost 7 million
Americans currently abuse prescription drugs [6]. Also, prescription drugs are involved in more than 8,500 deaths per year,
a 114% increase since 2000 [7].

The recent meta-analyses conducted by Mitchell and colleagues [22] on the ability of drug courts to reduce criminal
recidivism address many of these gaps. Findings from this
meta-analytic review support the ability of drug courts to reduce criminal recidivism. Although Mitchell and colleagues
did replicate previous findings indicating higher effect sizes for
less methodologically-rigorous evaluations, the authors note
that all of the methodologically rigorous evaluations provided
evidence of reduced criminal recidivism related to drug court
participation. Also, reductions in criminal recidivism associated
with drug court participation increased across longer durations
of study follow-up, with the authors concluding that “the available research suggests that adult drug court participants have
reduced recidivism during and after drug court treatment, and
these effects appear to last at least three years post-drug court
entry” (p. 68).

There are several possible explanations for this dramatic
upsurge in prescription drug abuse. Lax state oversight has allowed unregulated and fraudulent pain clinics to proliferate,
particularly in Florida [8]. Primary care physicians also have recently expanded their prescribing of opioids [9] while pharmaceutical companies have introduced various new formulations
[10]. Finally, there are few medication options for severe pain
other than opioids [11].
Prescription drug addiction in women

Drug courts reduce substance use. Whereas it is presumed
that the reduction in recidivism rates for drug court participants
is due to addressing their underlying substance use disorders,
very few studies have directly examined participant substance
use outcomes [23], specifically prescription drug abuse. Several
studies have examined the effect of drug court participation
on future drug use in general with positive effects [24,-30], but
only two of the studies report baseline prescription drug use
[24,29]. For example, Brewster [24] evaluated a drug court program and compared 184 participants to 51 comparable offenders. Baseline data revealed that prescription drugs were reported for 4.3% of the drug court sample vs. 2.0% of the comparison
sample with the majority reporting cocaine and marijuana as
primary drugs of choice. Outcome results found that rates of
positive drug tests were lower for the drug court sample than
for the comparison sample. The second study by Messina and
colleagues [29] compared outcomes for 150 female offenders
who participated in either a Gender Responsive (GR) drug court
program (N = 85) or a Mixed Gender (MG) drug court program
(N = 65). Opiate use was reported as primary drug of choice
for 14% overall (9% GR group vs. 20% MG group). Outcome results revealed that both the GR and MG groups had significant
reductions in drug and alcohol composite scores from baseline
to follow-up. Although these findings are positive, they do not
specifically address the issue of prescription drug use in female
offenders.

Powerful prescription painkillers pose a particular threat to
women. Unlike heroin and other street drugs, which are mainly
abused by men, women abuse prescription drugs at least as
often as men [12,13]. Over the past decade, two factors have
fueled this trend: (1) women are prescribed narcotic medications more frequently than men [14] and (2) women report
painkillers as their primary drug of abuse more often than men
[15]. As a result, the number of addicted women in the U.S.
continues to swell [16,17]. Not surprisingly, a segment of this
at-risk population becomes involved in crime related to their
prescription drug use. Women who are arrested with prescription drug addictions are often charged with doctor shopping,
possession of controlled substance, and drug trafficking. Facing
additional stressors such as homelessness, unemployment, and
inadequate child care, this population poses a daunting challenge for the traditional criminal justice system.
Drug court alternative
The punitive nature of the legal system has historically been
ineffective in meeting the needs of most substance-abusing offenders. Drug court represents a paradigm shift from punishment and incarceration to treatment, rehabilitation, support,
and community reintegration [18]. The presiding judge, substance abuse treatment provider, and offender interact on a
regular basis in a collaborative climate. This judicial model provides better monitoring of offenders compared to other forms of
community supervision. In return for possible dismal of charges
or reduced probation time, the offender must adhere to his or
her comprehensive and closely monitored treatment plan.

Program description
In 2008, the 6th Judicial Court received a three-year SAMHSA/CSAT grant to establish a drug court program serving female offenders with prescription drug abuse. The drug court
program is titled WeCan! (Women Empowered to Cope with
Addiction to Narcotics) and includes a judge; court-employed
case managers; substance abuse treatment providers; defense
attorneys; and the state Office of the Attorney General. Two
local substance abuse treatment agencies provided 12 weeks
of intensive outpatient treatment services using two EvidenceBased Program (EBP) models: Motivational Enhancement
Therapy/Cognitive Behavioral Therapy-12 (MET/CBT-12,31) and

Drug courts reduce criminal recidivism. The results of this alternative legal model are impressive. Both primary studies and
meta-analytic reviews indicate drug courts significantly reduce
criminal recidivism [19,20,21]. However, the evidence base supporting the ability of drug courts to reduce criminal recidivism
has been criticized for several methodological flaws [22]. Namely: 1) many drug court evaluations have been methodologically
weak, with very few rigorous experimental or quasi-experimenJournal of Addiction and Recovery
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Seeking Safety [32]. All WeCan! participants received both EBP
treatments regardless of which agency provided the treatment.
The focus of MET/CBT-12 is to teach participants how to function without drugs, avoid situations that lead to drug use, and
sensibly respond to relapses. Seeking Safety is a curriculum for
participants with a history of trauma and substance abuse and
focuses on coping skills and psychoeducation.

or memories occurring in the past year related to participant
trauma or other disorders of extreme stress [34]. In the current study, participant scores at baseline produced a reliability
coefficient of 0.89. Given the different period of time assessed
at the 12-month follow-up assessment (i.e., past 90 days versus
past year), only baseline data for the TSS are presented.
The GAIN Past 90 Day Substance Use scale was used to measure changes in participant self-reported substance use from
baseline to 12-month follow-up.

Aside from attending intensive outpatient addictions treatment, all WeCan! participants were required to attend monthly
judicial reviews, weekly AA/NA groups, and were also subjected
to one to two random drug screens per week. Although most
participants completed the treatment component within three
months, most remain in drug court for judicial reviews up to
one year. Program eligibility criteria included: (1) prescription
drug-related charges, (2) no history of violent criminal offenses,
(3) no diagnosis of severe mental illness, (4) no alleged sexual
perpetration, and (5) willingness to participate in drug court
treatment.

Criminal justice involvement. Information on participants’
arrest history was collected from an online database of legal
charges in Pinellas County for the 12-month period prior to
baseline and the 12-month period following baseline. Arrest
charges were categorized as: (1) possession charges, (2) DUI
charges, (3) prescription charges, (4) doctor shopping charges,
(5) trafficking charges, (6) property charges, (7) violent charges,
and (8) other charges. “Other charges” were less commonly observed and included general criminal justice offenses such as
violation of probation, failure to appear, and traffic violations.

Current study

Circumstances, Motivation, and Readiness [35]. The CMR is
an 18-item instrument designed to (1) measure motivation and
readiness for treatment and (2) predict retention in substance
abuse treatment. Responses to each item are rated on a Likert
scale ranging from (1) Strongly Agree to (5) Strongly Disagree.
We utilized the instrument’s Total score as well as the Motivation scale which assessed the internal recognition of the need
to change. Prior research produced scores with internal consistencies of .60-.81 for each CMR subscale [36]. In the current
study, participant scores at baseline produced Cronbach’s alpha
reliability coefficients of .91 (Motivation) and. 84 (Total score).

The current study examined preliminary treatment progress
of female drug court participants struggling with prescription
drug addiction. Specifically, this study utilized a 12-month longitudinal design to evaluate the following hypotheses: (1) Participants will reduce substance use from baseline to 12-month follow-up, (2) Participants will reduce criminal justice involvement
from one year prior to WeCan! program enrollment to one year
following WeCan! program enrollment, (3) Participants will increase motivation and readiness to change from baseline to 12month follow-up, and (4) Participants will increase their therapeutic alliance with counselor at 12-month follow-up. Findings
reported in this study are unique in that the WeCan! drug court
program provided gender-specific treatment services exclusively for women struggling with prescription drug abuse issues.

Working Alliance Inventory [37]. The WAI is 12-item instrument that assesses participants’ perspectives on the therapeutic rapport between participants and service providers. Each
item is rated on a 7-point Likert response scale. The WAI contains three subscales measuring (1) the therapeutic bond, (2)
client-provider agreement on therapeutic tasks, and (3) clientprovider agreement on therapeutic goals. There is also a composite scale measuring overall working alliance. The instrument
has been shown to produce reliable scores [38]. Meta-analytic
studies of the WAI consistently document the relationship between a strong working alliance and positive client outcomes
[39,40]. In the current study, the instrument was administered
at the 12-month follow-up interview. Participant scores produced Cronbach’s alpha reliability coefficients of .74-.92 on the
three subscales and .95 for the overall working alliance.

Method
Procedure
This study was approved by the institutional review board at
the University of South Florida. Baseline and 12-month followup data were gathered from female offenders participating in
the WeCan! drug court treatment program. Upon admission,
participants completed a comprehensive intake interview that
included several standardized measures. Participants then
completed a follow-up interview 12-months following their entry to the WeCan! program. The 12-month follow-up interview
included the standardized measures completed at baseline in
addition to a questionnaire assessing client-therapist rapport.
Interviews lasted approximately 90 minutes and were conducted in private.

Analyses
Simple descriptive statistics were used to depict participant
demographic characteristics, past-year symptoms of traumatic
experiences, and their working relationship with their counselor. Mc Nemar chi-square analyses were used to detect changes
over time in dichotomous variables related to criminal justice involvement and abstinence from alcohol and drugs. Dependent
t-tests were used to detect changes over time for continuous
variables related to substance use, criminal justice involvement,
and treatment motivation. Cronbach’s alpha coefficients were
computed to gauge the internal consistency of the standardized
measures. Given the large number of comparisons, Bonferroni
family-wise corrections were undertaken to control for Type I
error inflation. All tests were two-tailed.

Measures
Global Appraisal of Individual Needs [33]. The GAIN consists
of eight core sections designed to record participant demographic and clinical characteristics. Participants completed the
GAIN measure at baseline and at the 12-month follow-up interview in order to assess change over time.
The GAIN Traumatic Stress Scale (TSS) was used to measure
participant past-year symptoms of traumatic experiences at
baseline. The TSS is based on the Civilian Mississippi Scale for
PTSD and contains 13 items producing a count of symptoms
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Results

Characteristic

n

% or Mean (SD)

Participants

Past 90 day Income

-

$887 ($877)

Wages

-

$526 ($778)

Public assistance

-

$112 ($225)

Disability

-

$25 ($147)

Family/friends

-

$119 ($251)

Retirement

-

$20 ($199)

-

$28 ($146)

2

2.0

Baseline information was collected from the first 159 female
offenders who participated in the WeCan! program. Of these,
102 participants (64.2% of the total sample) also completed
measures at 12-month follow-up. To ensure the representativeness of the follow-up sample, analyses were performed using
Bonferroni family-wise corrections to examine potential baseline demographic and clinical differences between those completing only the baseline interview and those completing both
the baseline and follow-up interviews. No significant differences
emerged. In the absence of any significant differences, further
analyses were restricted to the sample completing measures at
both time points.

Other
Pregnant

Participant past-year symptoms of traumatic experiences
Table 2 presents participants’ self-reported past year symptoms of traumatic experiences. Of the thirteen indices of pastyear symptoms of traumatic experiences measured by the
Traumatic Stress Scale, participants reported experiencing an
average of 2.5 symptoms, although there was a great deal of
variability in the number of traumatic symptoms experienced
by participants (SD = 3.2). Participants most commonly reported: 1) when something reminded them of the past, that they
became distressed or upset (38.6%); 2) they felt guilty about
things that happened because they felt like they should have
done something to prevent them (36.6%); 3) they sometimes
used alcohol or other drugs to help themselves sleep or forget
about things that happened in the past (28.4%); 4) they had
nightmares about things in their past that really happened
(25.7%); and 5) they had a hard time expressing their feelings,
even to people they cared about (24.8%). Just over a fifth of
participants (21.8%) reported having any of the thirteen indices
of past-year traumatic symptoms for three or more months.

As can be seen in Table 1, the average age for participants
was 30.7 years, ranging from 18 to 57. The majority of participants were Caucasian (98%) with 6.9% reporting Hispanic ethnicity. The majority (79.4%) had finished high school, with 43.1%
reporting coursework beyond high school. Almost all (91.2%)
were in a stable housing situation at baseline. Of those housed,
41.2% reported living in a home or apartment they owned or
rented; 50% reported living in someone else’s residence. Nearly
half of participants (48.1%) were employed at least part-time
at baseline. Average monthly income for participants was $887
(SD = $877).
Table 1: Demographics characteristics (n = 102)
Characteristic

n

Age (years)

% or Mean (SD)
30.7 years (9.5)

Race
Caucasian

97

98.0

African-American

1

1.0

Native Hawaiian

1

1.0

Hispanic/Latino

7

6.9

Education (years)

-

12.9 (2.3)

Less than high school diploma

21

20.6

High school diploma

37

36.3

Some college

30

College diploma (Bachelor’s or
higher)

Table 2: Participant past-year symptoms of traumatic experiences (n = 102)
GAIN Traumatic Stress Scale Items

Ethnicity

n

% or
M (SD)

Participant past-year symptoms of traumatic experiences
When something reminds you of the past, you became distressed or upset

39

38.6

You felt guilty about things that happened because you felt
like youshould have done something to prevent them

37

36.6

29.4

Sometimes you used alcohol or other drugs to help yourself
sleep or forget about things that happened in the past

29

28.4

2

2.0

You had nightmares about things in your past that really
happened

26

25.7

Vocational technical, no diploma

1

1.0

Vocational technical diploma

11

10.8

You had a hard time expressing your feelings, even to the
people you cared about

25

24.8

Your dreams at night were so real that you awoke in a cold
sweat and forced yourself to stay awake

19

18.8

You lost your cool and exploded over minor, everyday
things

16

12.7

It seemed as if you have no feelings

11

10.9

You were frightened by your urges

9

8.9

You felt like you could not go on

7

6.9

You were afraid to go to sleep at night

Housing status
Someone else’s apartment

51

50.0

Own/rent apartment

42

41.2

Institution

6

5.9

Other housed

3

3.1

Full-time (35 + hours a week)

32

31.4

Part-time

17

16.7

Unemployed, looking for work

40

39.2

Unemployed, disabled

4

3.9

Unemployed, not looking for work

9

8.8

Employment status

Journal of Addiction and Recovery
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6.9

When you thought of things you had done, you wish you
were dead

1

1.0

Had any of the above problems for three or more months

22

Average number of TSS symptoms

4

21.8
2.5 (3.2)

MedDocs Publishers
12-months after program entry (M = .70, SD = 1.0) compared to
the 12-months prior to program entry (M = 1.3, SD = 0.7). Participants also had a significantly lower average number of charges
over time, t (100) = 4.68, p < .001, experienced by participants
at 12-months after program entry (M = 1.5, SD = 3.0) compared
to 12-months prior to program entry (M = 3.3, SD = 2.7).

Participant criminal justice involvement 12-months before
and after program enrollment
Arrest data were available for all but one participant in the
study sample. Additionally, two participants experienced their
index offense more than 12-months before program enrollment.
Criminal justice findings were re-analyzed excluding these cases
with similar results obtained; however, the average number of
charges experienced by participants in the 12-months prior to
baseline increased due to absence of those cases with no charges for this time period. Further, it should also be noted that arrests which occurred during the WeCan! program did not result
in termination from the program.

Most participants (67.3%) had a prior arrest for possession
charges compared to only 19.8% 12-months after program entry, χ2 (1) = 42.48, p < .001. There were several additional statistically significant reductions in other types of charges in the
12-months including: prescription fraud charges, χ2 (1) = 5.79, p
= .016; DUI charges, χ2 (1) = 9.10, p = .003; trafficking charges, χ2
(1) = 4.90, p = .028; and doctor shopping charges, χ2 (1) = 8.10,
p = .004. Other decreases in the number of charges incurred by
participants observed included the average number of possession charges, t (99) = 4.39, p < .001; prescription fraud charges,
t (100) = 2.88, p = .005; DUI charges, t (100) = 3.30, p = .001;
doctor shopping charges, t (100) = 2.66, p = .005; and property
charges, t (100) = 2.23, p = .028.

As can be seen in Table 3, a significantly smaller proportion
of participants experienced an arrest and associated criminal
charge(s) in the 12-months following WeCan! program entry
(43.6%) compared to the 12-months prior to program entry
(98.0%), χ2 (1) = 51.16, p < .001. It should be noted the number of charges exceed the number of arrests due to the fact
that an individual may have multiple charges during one arrest
incident. There was a significant difference in the number of arrests, t (100) = 5.51, p < .001, experienced by participants in the

Table 3: Participant criminal justice involvement 12-months before and 12-months following program enrollment (n = 102)

Participants with arrest history data

Total arrests

12-months before program
enrollment

12-months following program
enrollment

na

%

na

%

99

98.02

44

43.6

M (SD)b
1.3 (0.7)

Total charges

99

98.0

68

67.3

20

16

15.8

DUI charges

13

12.9

0.1 (0.3)
2

Doctor shopping charges

11

10.9

0.0 (0.2)
1

Trafficking charges

13

12.9

0.0 (0.1)
1

Property charges

16

15.8

1.0 (0.6)
8

7.9

0.2 (0.6)
Violent charges

7

7.1

1.0

0.1 (0.5)
“Other” charges

22

22.0
0.4 (1.1)
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.028
.077

0.0 (0.1)
23

.128
.080

0.1 (0.4)
1

.005
.003

1.0

0.2 (0.7)

.001
.004

1.0

0.4 (1.5)

.009
.003

2.0

1.4 (1.5)

<.001
.016

5.9

0.3 (0.8)

<.001
<.001

19.8
0.6 (1.6)

6

<.001
<.001

1.5 (3.0)

3.3(2.7)
Prescription fraud charges

<.001

43.6

3.3 (2.7)
Possession charges

M (SD)b
0.7 (1.0)

44

Significance1

23.0

.060
.999

0.6 (1.7)

.264

MedDocs Publishers
Note: Some missing data; valid percentages displayed.
1. A Bonferroni family-wise correction was made to control for likelihood of Type I error inflation. Specifically, the significance level for main study
hypotheses related to proportion of participants experiencing any arrest and any charge as well as total number of arrests and total number
of charges over time was adjusted to p = .0125 (.05 / 4 tests). No Bonferroni family-wise corrections were made for subsequent exploratory
analyses related to likelihood as well as total number of specific charges incurred by participants over time; subsequent exploratory analyses
were evaluated at p < .05. Significant p-values are bolded.
2. Arrest data were accessible for all but one participant whose case was closed. It should be noted that some participants’ (n = 2) original
offense(s) that brought them into drug court occurred more than 12-months before their entry into the Program; hence that information was not
captured in this study’s arrest data
a.Percentages represent the percent of participants with one or more of the arrests/charges indicated.
b. Measures of central tendency are based on the average number of arrests/charges experienced by the sample.

Participant substance use in past 90 days
pants reported use at baseline; 12-months later only 6.9% (χ2
[1] = 38.03, p <.001). Specifically, 38.2% of participants reported
painkiller/opiate use within the past 90 days at baseline vs. only
5.9% at 12-month follow-up (χ2 [1] = 31.03, p <.001). Additionally, 27.5% of participants reported anti-anxiety/tranquilizer use
within the past 90 days at baseline vs. only 3.9% at 12-month
follow-up (χ2 [1] = 18.89, p <.001). There also were significant
reductions for alcohol (t [100] = 4.17, p< .001),marijuana (t [100
= 3.84, p< .001), painkillers/opiates (t [100] = 3.94, p< .001), and
anti-anxiety/tranquilizers (t [101] = 2.92, p = .004).

Table 4 presents information of participants’ self-reported
substance use. WeCan! participants reported significant reductions in alcohol and illicit drug use from baseline to 12-month
follow-up. At baseline, 60.8% of participants reported alcohol
use within the past 90 days; 12-months later only 15.7% did
(χ2 [1] = 37.50, p <.001). At baseline, 79.4% of participants reported illicit drug use within the past 90 days; 12-months later
only 18.6% did (χ2 [1] = 60.02, p <.001). Specifically, 38.2% of
participants reported marijuana use within the past 90 days at
baseline vs. only 2.0% at 12-month follow-up (χ2 [1] = 35.03,
p <.001). In terms of prescription drug use, 46.1% of partici-

Table 4: Substance use change over time from baseline to 12-month follow-up (n = 102)
Baseline

12-month

Significance1

n

% or M (SD)

n

% or M (SD)

Alcohol

62

60.8

16

15.7

<.001

Illicit drugs

81

79.4

19

18.6

<.001

Marijuana

39

38.2

2

2.0

<.001

Crack

6

5.9

3

2.9

.371

Cocaine

6

5.9

3

2.9

.505

Heroin

2

2.0

0

0.0

a

Prescription drugs

47

46.1

7

6.9

<.001

Pain killers, opiates

39

38.2

6

5.9

<.001

Anti-anxiety, tranquilizers

28

27.5

4

3.9

<.001

Downers, sedatives

2

2.0

1

1.0

.999

7.0 (14.4)

0.9 (3.3)

<.001

Marijuana

6.2 (16.4)

0.3(3.0)

<.001

Crack

0.6 (3.3)

0.1 (0.5)

.119

Cocaine

0.2 (1.2)

0.1 (0.5)

.368

Heroin

0.5 (4.5)

0.0 (0.0)

.289

Pain killers, opiates

10.9 (23.9)

2.0 (9.9)

<.001

Anti-anxiety, tranquilizers

3.4 (11.2)

0.3 (2.0)

.004

Downers, sedatives

0.1 (1.0)

0.1 (1.4)

.909

Percent of participants using past 90 days:

Number of days in past 90 using:
Alcohol
Illicit drugs

2

Prescription drugs2

Note: Some missing data; valid percentages displayed.
1. Two Bonferroni family-wise corrections were made to control for likelihood of Type I error inflation, separated by
type of analyses (percentage of participants using specific substances in the past 90 days; number of days participants
Journal of Addiction and Recovery
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reported using specific substances in the past 90 days). Specifically, the significance level related to the proportion of
participants using specific substances was adjusted to p = .005 (.05 / 10 tests); the significance level related to the
number of days participants reported using specific substances was adjusted to p = .00625 (.05 / 8 tests). P-values for
significant tests are bolded.
2. It was not possible to create a composite variable regarding the number of days participants reported any type of
drug use in the past 90 days.
a. Could not be computed as one variable was a constant
Participant circumstances, motivations, and readiness
(CMR)
As seen in Table 5, participants reported significantly increased motivation at 12-month follow-up (M = 22.9 [SD = 5.6])
than at baseline (M = 16.2 [SD = 6.8]), t (66) = -6.22, p< .001.
Participants also reported significantly higher total scores on
the CMR from baseline (M = 54.0, SD = 13.8) to 12-month follow-up (M = 70.5, SD = 23.9), t (63) = -4.60, p< .001.
Table 5: Participant scores on the Circumstances, Motivation, Readiness (CMR) scale from baseline to 12month follow-up (n = 102)
Baseline

12-month

Significance1

M (SD)

M (SD)

16.2 (6.8)

22.9 (5.6)

<.001

54.0 (13.8)

70.5(23.9)

<.001

Motivation
Internal recognition of the need to change
Total score

Note: Some missing data; valid percentages displayed. Analyses are restricted to only the CMR subscale
Motivation as well as the CMR Total Score scale given the poor reliability of scores produced for other CMR
subscales (i.e., Circumstances 1, Circumstances 2, and Readiness for Treatment).
1. A Bonferroni family-wise correction was made to control for likelihood of Type I error inflation. Specifically, the
significance level was adjusted to p = .025 (.05 / 2 tests). P-values for significant tests are bolded.

Participant ratings of therapeutic alliance

gram entry compared to 12-months after program enrollment.
In the 12-months prior to program entry, the most common
arrest charge incurred by participants was drug possession.
However, only a small percentage of participants had possession charges 12-months after program enrollment. Additionally,
participants also had significant reductions in DUI, prescription
fraud charges, doctor shopping, and trafficking charges. Results
from this study documenting reduced criminal behavior for WeCan! participants are consistent with the large body of literature supporting the ability of drug courts to reduce participant
criminal recidivism [22].

In conjunction with these findings, participants reported
strong relationships with their court-appointed counselors.
Participants reported positive working relationships regarding
treatment task (M = 23.1 [SD = 4.9]), bond with their counselor
(M = 22.8 [SD = 6.5]), treatment goals (M = 22.3 [SD = 4.9]), and
overall working alliance with their counselor (M = 68.2 [SD =
15.5]).
Discussion
This 12-month evaluation study of a therapeutic drug court
tailored for female offenders with prescription drug abuse issues examined participant self-reported substance use and
symptoms of traumatic experiences, criminal justice involvement, motivation and readiness to change, and therapeutic alliance. Results of this study supported the appropriateness of the
treatment modality employed to address participant substance
use. Specifically, the WeCan! program incorporated a treatment
modality specifically tailored to deal with the relationship between substance abuse and trauma symptoms [32]. At baseline, participants reported high levels of self-reported past-year
trauma symptoms and endorsed several items including using
alcohol or drugs as a coping strategy. These results support the
need for targeted interventions to provide trauma-informed
care for substance use disorders.

WeCan! participants also significantly reduced their levels
of self-reported substance use across the 12-months after their
program entry. This is impressive considering the length of treatment is approximately three to four months and reductions in
alcohol and drug use decreased significantly at 12-month follow-up. This improvement included the substances most commonly abused by participants in the past: alcohol, marijuana,
and prescription painkillers. This study adds to the small but
growing body of literature supporting the ability of drug courts
to reduce participant substance use.
Participants reported significantly increased motivation or
internal recognition of the need to change at 12-month followup. Additionally, most participants were pleased with the therapeutic bond developed with program staff. They felt there was
a shared client-counselor vision regarding therapeutic tasks and
goals. These findings are particularly impressive given the potential for coercive relationships when engaged in the judicial
system and support the professionalism of treatment providers.

WeCan! participants significantly reduced their criminal justice involvement over the course of their first year of participation when compared to the year prior to their WeCan! involvement. There was a significant decrease in the total number of
participant arrests that occurred in the 12-months before proJournal of Addiction and Recovery
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It is likely that high participant motivation, strong working alliances, and a positive therapeutic environment all contributed
to reduced substance use over the course of the study period.

and emergency department visits. J Addict Disord. 2008;
27: 1–11.

Limitations
Conclusions based on this program evaluation are restricted
by the use of a pretest-posttest study design without a comparison group. Another limiting factor is the reliance on unverifiable, self-report data related to past substance use. This
limitation is further compounded by the serious legal ramifications for non-compliance (e.g., self-reported drug use) faced
by drug court participants. Finally, it is impossible to determine
the long-term outcomes for WeCan! participants based on this
study’s 12-month follow-up. Future research should follow offenders for several years after program graduation.
Conclusions
Study findings suggest that the WeCan! program is meeting
programmatic goals for its target population of female offenders with prescription drug abuse issue. Increasing numbers of
female offenders abusing prescription painkillers are burdening an already overtaxed legal system. Innovative programs like
WeCan! offer a fundamentally different way of dealing with a
problem that threatens the public health of many communities
across the United States, especially in Florida. The significant
reductions in substance use and criminal justice involvement
suggest this type of program should be of particular interest to
policymakers in these difficult economic and social times. Assuming future research replicates the positive findings of this
study, specialized drug courts could help reshape the judicial
system in the coming decades. While the cost of quality substance abuse treatment is high, the costs of ongoing addiction,
incarceration, and criminal recidivism are much higher—both in
dollars spent and lives lost.
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